OncoSecs Tavo in Combination with Keytruda Demonstrates Encouraging Interim Results in Heavily Pretreated Patients with Metastatic TNBC

OncoSec’s Tavo in Combination with Keytruda Demonstrates Encouraging Interim Results in Heavily Pretreated Patients with Metastatic TNBC

11:08 EDT 23 May 2019 | Speciality Pharma Journal

SAN DIEGO and PENNINGTON, N.J., May 22, 2019 /PRNewswire/ — OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a late-stage cancer biotechnology company developing gene-based intratumoral immunotherapies, today announces interim data from KEYNOTE-890, an ongoing Phase 2 study of TAVO™ (intratumoral IL-12) in combination with KEYTRUDA® in patients with heavily pretreated, metastatic, chemotherapy refractory triple negative breast cancer …

More From BioPortfolio on "OncoSec’s Tavo in Combination with Keytruda Demonstrates Encouraging Interim Results in Heavily Pretreated Patients with Metastatic TNBC"